Esomeprazole ((S)-Omeprazole) hemistrontium 是一种有效的具有口服活性质子泵 (Proton pump) 抑制剂，可通过抑制胃壁细胞中的H+, K+-ATPase来降低酸分泌，并可用于胃食管反流疾病的研究。

Esomeprazole ((S)-Omeprazole) hemistrontium is a potent and orally active proton pump inhibitor and reduces acid secretion through inhibition of the H +, K + -ATPase in gastric parietal cells. Esomeprazole hemistrontium has the potential for symptomatic gastroesophageal reflux disease research [1] [2] [3].

Esomeprazole (25-100 μM; 20 hours; MDA-MB-468 cells) hemistrontium treatment suppresses growth of triple-negative breast cancer cell in vitro in a dose-dependent manner through increase in their intracellular acidification [1]. Cell Viability Assay [1] Cell Line: MDA-MB-468 cells Concentration: 25 μM, 50 μM, 75 μM, 100 μM Incubation Time: 20 hours Result: Suppressed growth of triple-negative breast cancer cell in vitro in a dose-dependent manner.

Esomeprazole (30-300 mg/kg; oral gavage; daily; for 19 or 11 days; C57BL/6J mice) hemistrontium treatment significantly inhibits the progression of fibrosis throughout the lungs of the animals. Esomeprazole also reduces circulating markers of inflammation and fibrosis [2]. Animal Model: C57BL/6J mice (8-weeks old, 25-30 g) treated with cotton smoke-induced lung injury [2] Dosage: 30 mg/kg, 300 mg/kg Administration: Oral gavage; daily; for 19 or 11 days Result: Significantly inhibited the progression of fibrosis throughout the lungs of the animals.

914613-86-8

C17H18N3O3SSr+

388.22

(< 1 mg/ml refers to the product slightly soluble or insoluble )
Powder: -20°C for 3 years
In solvent: -80°C for 2 years